{"id":"W4393088686","doi":"10.1158/1538-7445.am2024-684","title":"Abstract 684: DT-9045, a novel PAR2 inhibitor with best-in-class properties that reduces resistance to both EGFR-targeting therapies and immunotherapy in oncology models","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Aegera Therapeutics (Canada); Université de Montréal","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Internal medicine; Cancer; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009948714,0.000492655,0.0003906074,0.0002310502,0.00009993041,0.0002417396,0.0002541479,0.0003103707,0.002841149],"category_scores_gemma":[0.00006038028,0.0001504179,0.0002885998,0.000167599,0.0001040854,0.0002255752,0.0001471643,0.0006457372,0.000867699],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002147958,"about_ca_system_score_gemma":0.0001750685,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004510149,"about_ca_topic_score_gemma":0.0005157539,"domain_scores_codex":[0.99993,0.00001089075,0.000006008757,0.00001645036,0.00001472962,0.00002187486],"domain_scores_gemma":[0.9999729,0.000001828083,0.000007262496,0.000002219942,0.000003353387,0.00001243076],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002540811,0.0008142283,0.0004139912,0.0003397886,0.00009293956,0.0001908466,0.00002411806,0.0005789167,0.9584728,0.0004972119,0.003083707,0.03295067],"study_design_scores_gemma":[0.002171417,0.01096202,0.006940813,0.00002717292,0.000246814,0.002054838,0.00002114107,0.002786627,0.9421799,0.0001341997,0.03244546,0.00002971624],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9635579,0.01518219,0.006073505,0.0006084876,0.0003193548,0.0002967197,0.002342687,0.000631189,0.01098795],"genre_scores_gemma":[0.9815291,0.004602247,0.003004683,0.0003980648,0.00005918465,0.0001048583,0.002375017,0.00004785643,0.007879038],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002841149,"threshold_uncertainty_score":0.009504557,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1920960856307969,"score_gpt":0.442190751604122,"score_spread":0.2500946659733251,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}